MEDIUM confidence: 100% data completeness, but the composite (56) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 4.1%/yr (revenue basis).
Base free cash flow $2.1B (avg FY2023–FY2025; latest year $2.6B) · equity value $29.5B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net insider -$184K over 180 days (0 open-market buys, 4 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $74 avg across 3 analysts.
Buy-rated share 45% → 45% over ~3 months (+0pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Oct 2026 | $1.46 | $1.49 | +2.1% |
| Jul 2026 | $1.38 | $1.37 | -0.7% |
| Apr 2026 | $1.34 | $1.40 | +4.5% |
| Feb 2026 | $1.32 | $1.35 | +2.3% |
| Oct 2025 | $1.30 | $1.39 | +6.9% |
| Jul 2025 | $1.26 | $1.31 | +4.0% |
| Apr 2025 | $1.20 | $1.23 | +2.5% |
| Feb 2025 | $1.12 | $1.21 | +8.0% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $18.5B— | $19.4B+5.0% | $19.4B-0.4% | $19.7B+2.0% | $21.1B+7.0% |
| EPS (dil.) | $4.05— | $4.41+8.9% | $4.21-4.5% | $4.51+7.1% | $4.55+0.9% |
| Free Cash Flow | $2.2B— | $2.2B+0.9% | $2.0B-10.0% | $1.8B-9.2% | $2.6B+42.0% |
| Gross Margin | 37.3% | 35.9%-1.4pp | 34.6%-1.4pp | 34.3%-0.2pp | 33.7%-0.6pp |
| Operating Margin | 15.3% | 15.3%+0.0pp | 13.9%-1.4pp | 14.7%+0.8pp | 16.7%+2.1pp |
| Net Margin | 11.5% | 11.8%+0.2pp | 11.0%-0.8pp | 11.3%+0.4pp | 10.6%-0.8pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
The QScore of 56 for CTSH indicates a neutral outlook, driven by its strong value scores, with a P/E of 11.9 and P/B of 2.0, which suggest the stock trades at a reasonable multiple. However, growth scores are relatively low, at 43, due to modest revenue and EPS growth. Momentum scores are higher, at 57, driven by a recent 18% return over the past three months, and the stock exhibits strong risk characteristics, with a beta of 0.9 and low volatility. The long-term and short-term scores are relatively aligned, with only a 2-point difference.